Oruka Therapeutics, Inc.
Clinical trials sponsored by Oruka Therapeutics, Inc., explained in plain language.
A biopharmaceutical company developing novel antibody therapies for inflammatory skin diseases.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- New drug ORKA-002 tested in humans for the first time Results expected Jan 2027 (estimated)
- New psoriasis drug shows promise in Mid-Stage trial Results expected Jun 2027 (estimated) May already have reported ↗
-
New psoriasis drug ORKA-001 tested for Long-Term safety
Disease control Recruiting nowThis study is testing the long-term safety and effectiveness of a drug called ORKA-001 for people with moderate-to-severe plaque psoriasis. It is an open-label extension, meaning everyone gets the drug, and it includes 240 adults who already completed a previous trial with ORKA-0…
Phase 2 • Sponsor: Oruka Therapeutics, Inc. • Aim: Disease control
Last updated Sep 06, 2026 00:00 UTC
-
Can a new injection quiet the painful lumps of hidradenitis suppurativa?
Disease control Recruiting nowThis trial tests an investigational drug called ORKA-002 in adults with moderate-to-severe hidradenitis suppurativa, a chronic skin condition that causes painful lumps and tunnels under the skin. Participants receive either ORKA-002 or a placebo by injection, and researchers meas…
Phase 2 • Sponsor: Oruka Therapeutics, Inc. • Aim: Disease control
Last updated Sep 02, 2026 00:00 UTC
-
New psoriasis drug shows promise in Mid-Stage trial
Symptom relief Recruiting nowThis study tests a new medicine called ORKA-002 for adults with moderate-to-severe plaque psoriasis. About 160 participants will receive either the drug or a placebo to see if it clears skin and is safe. The goal is to find the best dose and check for side effects over 16 weeks.
Phase 2 • Sponsor: Oruka Therapeutics, Inc. • Aim: Symptom relief
Last updated Aug 12, 2026 00:00 UTC